NCT05506592Unknown不适用
Evaluation of the Efficacy of an Anti Dandruff Shampoo Against Placebo on Dandruff and Scalp Microflora Composition After 4 Weeks of Treatment and 4 Weeks of Relapse
L'Oreal2 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2022年10月最近更新:
适应症
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 60
- 试验地点
- 2
- 主要终点
- Analysis of microflora from swabs for fungi quantification
研究概览
简要总结
A shampoo containing SeS2 was evaluated versus placebo on healthy subjects suffering from dandruff in order to assess clinical benefits and its impact on fungal and bacterial scalp microbiota.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy male or female volunteers;
- •Age: 18 to 60 years old included;
- •Phototype (Fitzpatrick): I to IV;
- •Subjects with hair length > 2 cm, and preferentially shorter than shoulder length;
- •Females of childbearing potential, who are sexually actives, using an effective contraceptive method* for at least one month before the beginning of the study, and throughout the study;
- •Subjects exhibiting moderate to severe dandruff status of scalp at screening
- •Subjects having at inclusion visit Day 0:
- •total dandruff score (adherent + non-adherent) > or = 4.5 (ranging from 0 to 10);
- •adherent dandruff score > or = 2.5 (ranging from 0 to 5);
- •no limit for non-adherent dandruff score;
- •Subjects having on inclusion Day 0, 2 areas with dandruff (score > 2.5) (one of 1x1cm2, the other of 2 x 2cm2) and 2 areas without dandruff (score < 1) (one of 1x1cm2, the other of 2 x 2cm2) in the vertex if possible
- •Subjects usually using a shampoo 3 times/week and willing to have three times/week shampoos during the course of the study;
- •Subjects agreeing to use only the supplied shampoo during all the study;
- •Subjects agreeing to have 4 hair areas on the scalp (2 areas of approximately 2 cm x 2 cm and 2 areas approximately 1cmx1cm) for micro flora sample taking (swabs);
- •Subjects agreeing to have hair cut around the 4 identified areas (zone of 1x0.5cm cut on the high corner of each area sampling)
- •Subjects who demonstrate understanding of the study and willingness to participate as evidenced by voluntary written informed consent and have received a signed and dated copy of the informed consent form.
- •Subject affiliated to a social security or insurance system;
- •Subjects willing to comply to the study requirements;
- •Subjects who are willing not to take part in another clinical study in another investigating centre;
- •Subjects who agree to give accurate personal information;
- •Subjects who are able to attend all study visits. * The effective contraceptive methods: sexually active females of childbearing potential should either be surgically sterile (oophorectomy, hysterectomy or tubal ligation), or should use a medically accepted contraceptive regimen: systemic contraceptive (oral, implant, injection), diaphragm or cervical cap with intravaginal spermicide,intravaginal device, intrauterine device (IUD), condom with spermicide
排除标准
- •Inclusion Criteria
- •Healthy male or female volunteers;
- •Age: 18 to 60 years old included;
- •Phototype (Fitzpatrick): I to IV;
- •Subjects with hair length > 2 cm, and preferentially shorter than shoulder length;
- •Females of childbearing potential, who are sexually actives, using an effective contraceptive method* for at least one month before the beginning of the study, and throughout the study;
- •Subjects exhibiting moderate to severe dandruff status of scalp at screening and at D-3;
- •Subjects having at inclusion visit Day 0:
- •total dandruff score (adherent + non-adherent) > or = 4.5 (ranging from 0 to 10);
- •adherent dandruff score > or = 2.5 (ranging from 0 to 5);
- •no limit for non-adherent dandruff score;
- •Subjects having on inclusion Day 0, 2 areas with dandruff (score > 2.5) (one of 1x1cm2, the other of 2 x 2cm2) and 2 areas without dandruff (score < 1) (one of 1x1cm2, the other of 2 x 2cm2) in the vertex if possible
- •Subjects usually using a shampoo 3 times/week and willing to have three times/week shampoos during the course of the study;
- •Subjects agreeing to use only the supplied shampoo during all the study;
- •Subjects agreeing to have 4 hair areas on the scalp (2 areas of approximately 2 cm x 2 cm and 2 areas approximately 1cmx1cm) for micro flora sample taking (swabs);
- •Subjects agreeing to have hair cut around the 4 identified areas (zone of 1x0.5cm cut on the high corner of each area sampling)
- •Subjects who demonstrate understanding of the study and willingness to participate as evidenced by voluntary written informed consent and have received a signed and dated copy of the informed consent form.
- •Subject affiliated to a social security or insurance system;
- •Subjects willing to comply to the study requirements;
- •Subjects who are willing not to take part in another clinical study in another investigating centre;
- •Subjects who agree to give accurate personal information;
- •Subjects who are able to attend all study visits. * The effective contraceptive methods: sexually active females of childbearing potential should either be surgically sterile (oophorectomy, hysterectomy or tubal ligation), or should use a medically accepted contraceptive regimen: systemic contraceptive (oral, implant, injection), diaphragm or cervical cap with intravaginal spermicide,intravaginal device, intrauterine device (IUD), condom with spermicide
- •Exclusion Criteria
- •Subjects with any systemic disorder or skin disease that would, in the investigator's judgment, significantly affect the interpretation of the study results (e.g. seborrheic dermatitis which shows the syndrome of invasion plaque and/or pityriasis amiantacea, atopic dermatitis, eczema or psoriasis);
- •Subjects with cutaneous affection of the scalp (psoriasis, atopic dermatitis, seborrheic dermatitis which shows the syndrome of invasion plaque and/or pityriasis amiantacea, ...);
- •Female subjects who are known to be pregnant or who are intending to become pregnant over the duration of the study;
- •Female subjects who are currently breast-feeding or have been breast-feeding in the 6 months prior to the start of the study;
- •Male subjects with alopecia grade ≥ V according to Hamilton-Norwood patterns, female subjects with alopecia grade I, II or III according to Ludwig patterns;
- •Subjects with frizzy hair influencing the scoring of dandruff;
- •Subjects with significant white hair influencing the scoring of dandruff;
- •Subjects who have skin marks on the scalp that could interfere with the assessments (e.g. pigmentation, tattoo, scarring etc.);
- •Subjects who have used products for the scalp (dyeing, bleaching, permanent waving and straightening ...) within the three weeks prior to the study;
- •Subjects who have used anti-dandruff treatment (per os or topical) during the last three weeks before the start of the study;
- •Subjects who have used cosmetic anti-hairloss treatment (per os or topical) during the last three months before the start of the study, or/and subject who has used medical anti-hair loss treatment (per os or topical, ex: Minoxidil, finasteride, etc...) during the last six months before the start of the study;
- •Subjects with personal history of allergy and/or particular reactivity to antidandruff products, and/or to cosmetic products containing tensioactive agents (soaps, shower gel, conditioner ...), and/or to latex;
- •Subjects who have taken any systemic drug containing corticoids, or anti-fungal, or antibiotics, or any prolonged use of topical drug containing corticoids, or anti-fungal, or antibiotics, or any prolonged use of non-steroidal anti-inflammatory, or anti-histaminic within one month prior to the study;
- •Subjects who have taken retinoic acid since less than three months prior to the study;
- •Subjects receiving other medication which, in the opinion of the investigator, will affect either the scientific validity of the study or the subject's wellbeing.
- •Subjects with a history of medical/surgical events (or surgical events planned) which, in the opinion of the investigator, will affect either the scientific validity of the study or the subject's wellbeing;
- •Immunosuppressed subject;
- •Subjects with medical history of skin cancer;
- •Subjects who have started, stopped or changed his/her hormonal treatment (including contraceptive pill) in the previous one month prior to the study;
- •Subjects practicing regularly water sports and/or having regularly sauna sessions;
- •Subjects exposed to the sun or UV rays in an excessive way during the last month prior to the study (according to the investigator);
- •Subjects deprived of liberty by adjunction or by official decision;
- •Subjects who are participating or who has participated to a clinical study for which the exclusion period is not finished;
- •Subjects unable to be contacted by phone;
- •Subjects belonging to the staff of the investigating centre
结局指标
主要结局
Analysis of microflora from swabs for fungi quantification
时间窗: 1 month
malassezia qPCR
Analysis of microflora from swabs for bacteria quantification
时间窗: 1 month
Cutibacterium qPCR
Analysis of microflora from swabs for bacteria diversity
时间窗: 1 month
sequencing 16S
Analysis of microflora from swabs for fungi diversity
时间窗: 1 month
sequencing ITS
次要结局
- Grading of Dandruff severity(1 month)
研究者
研究点 (2)
Loading locations...
相似试验
Unknown
不适用
Effects on the Scalp Lipids and TEWL of a 1% Selenium Disulfide and 1% Salicylic Acid Antidandruff Shampoo on Dandruff ScalpDandruffNCT05503706L'Oreal40
尚未招募
Unknown
Anti-Dandruff Shampoo - EFFICACYCTRI/2023/03/050848GODREJ INDUSTRIES LTD.
已完成
不适用
Seborrheic Dermatitis: Ketoconazole 2% Foam Versus Ketoconazole 2% ShampooSeborrheic DermatitisNCT01203189St. Louis University23
尚未招募
3 期
Ayurved oil for DandruffCTRI/2020/08/027472Parul Institute of Ayurved
已完成
不适用
Evaluation of anti-dandruff Efficacy of Test products On Healthy Human SubjectsCTRI/2017/05/008658ITC LIMITED ITC Life Sciences and Technology Centre47